Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM, Chanh TC. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infection and Immunity 69(2):1175–1177.

Freedman A, Afonja O, Chang MW, Mostashari F, Blaser M, Perez-Perez G, Lazarus H, Schacht R, Guttenberg J, Traister M, Borkowsky W. 2002. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 287(7):869–874.

Friedlander AM. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Current Clinical Topics in Infectious Diseases 20:335–349.

Gallagher TC, Strober BE. 2001. Cutaneous Bacillus anthracis infection. New England Journal of Medicine 345(22):1646–1647.

Gunzenhauser JD, Cook JE, Parker ME, Wright I. 2001. Acute side effects of anthrax vaccine in ROTC cadets participating in advanced camp, Fort Lewis, 2000. MSMR (Medical Surveillance Monthly Report) 7(5):4–14.

Henderson DA. 1999. The looming threat of bioterrorism. Science 283(5406):1279–1282.

Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K. 1999. Anthrax as a biological weapon: medical and public health management. JAMA 281(18): 1735–1745.

IOM (Institute of Medicine). 1991. Howson CP, Howe CJ, Fineberg HV, eds. Adverse Effects of Pertussis and Rubella Vaccines. Washington, D.C.: National Academy Press.

IOM. 1994. Stratton KE, Howe CJ, Johnston RB, eds. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, D.C.: National Academy Press.

IOM. 2000a. An Assessment of the Safety of the Anthrax Vaccine: A Letter Report. Washington, D.C.: National Academy Press.

IOM. Fulco CE, Liverman CT, Sox HC, eds. 2000b. Gulf War and Health. Washington, D.C.: National Academy Press.

Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M, Fisk TL, Zaki S, Popovic T, Meyer RF, Quinn CP, Harper SA, Fridkin SK, Sejvar JJ, Shepard CW, McConnell M, Guarner J, Shieh WJ, Malecki JM, Gerberding JL, Hughes JM, Perkins BA. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerging Infectious Diseases 7(6):933–944.

Marshall E. 2000. Bioterrorism. DOD retreats on plan for anthrax vaccine. Science 289(5478): 382–383.

Mazzuchi JF, Claypool RG, Hyams KC, Trump D, Riddle J, Patterson RE, Bailey S. 2000. Protecting the health of U.S. military forces: a national obligation. Aviation, Space, and Environmental Medicine 71(3):260–265.

Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, Yampolskaya O. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266(5188):1202–1208.

Mina B, Dym JP, Kuepper F, Tso R, Arrastia C, Kaplounova I, Faraj H, Kwapniewski A, Krol CM, Grosser M, Glick J, Fochios S, Remolina A, Vasovic L, Moses J, Robin T, DeVita M, Tapper ML. 2002. Fatal inhalational anthrax with unknown source of exposure in a 61-year-old woman in New York City. JAMA 287(7):858–862.

Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFN gamma-induced release of NO and TNFalpha. FEBS Letters 462(1-2):199–204.

Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20(5–6):972–978.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement